Fisher & Paykel Healthcare (FRA:FPLB) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:FPLB Fisher & Paykel Healthcare Corp Ltd FRA:FPLB
95 GF Score
Price €21.80
GF Value €22.56
! 3 Warning Signs
View Full Analysis

What is Fisher & Paykel Healthcare Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Fisher & Paykel Healthcare  (FRA:FPLB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Fisher & Paykel Healthcare Cyclically Adjusted PS Ratio Related Terms


Fisher & Paykel Healthcare Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Fisher & Paykel Healthcare's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fisher & Paykel Healthcare Cyclically Adjusted PS Ratio Chart

Fisher & Paykel Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.49 11.01 9.24 10.51 10.36

Fisher & Paykel Healthcare Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.17 12.24 10.44 10.51 10.28

FRA:FPLB vs ISRG, BDX, RMD: Cyclically Adjusted PS Ratio Comparison

For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fisher & Paykel Healthcare Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fisher & Paykel Healthcare's Cyclically Adjusted PS Ratio falls into.


FRA:FPLB
95GF Score
Fisher & Paykel Healthcare Corp Ltd FRA:FPLB
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fisher & Paykel Healthcare Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Fisher & Paykel Healthcare's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Mar26 is calculated as:

For example, Fisher & Paykel Healthcare's adjusted Revenue per Share data for the fiscal year that ended in Mar26 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar26 (Change)*Current CPI (Mar26)
=2.005/136.8867*136.8867
=2.005

Current CPI (Mar26) = 136.8867.

Fisher & Paykel Healthcare Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201703 0.978 102.231 1.310
201803 1.024 103.355 1.356
201903 1.091 104.889 1.424
202003 1.281 107.547 1.630
202103 1.931 109.182 2.421
202203 1.698 116.747 1.991
202303 1.636 124.517 1.799
202403 1.687 129.526 1.783
202503 1.896 132.798 1.954
202603 2.005 136.887 2.005

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Fisher & Paykel Healthcare (FRA:FPLB) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of €21.80 is trading 3.4% below its estimated GF Value™ of €22.56.

Key valuation signals for FRA:FPLB:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €22.56 vs. price of €21.80 (3.4% below fair value)
  • GF Score™: 95/100 with 3 warning signs

No single metric tells the full story. See the FRA:FPLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fisher & Paykel Healthcare Business Description

Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
95GF Score

Get the complete analysis for FRA:FPLB

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.80
Price
€22.56
GF Value